# EDGAR Filing Document

**Accession Number:** 0002070534
**File Stem:** 0001104659-26-075797
**Filing Date:** 2026-6
**Character Count:** 17981
**Document Hash:** c793378833b7bee7ab0e0a36c7033ca6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-075797.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001104659-26-075797

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SL Science Holding Ltd
- **CENTRAL INDEX KEY:** 0002070534
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95763
- **FILM NUMBER:** 261103400

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 11/F, NO. 479 CHONGYANG ROAD
- **STREET 2:** NANGANG DISTRICT
- **CITY:** TAIPEI CITY
- **PROVINCE COUNTRY:** F5
- **ZIP:** 115010
- **BUSINESS PHONE:** 886-2-26516826

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 11/F, NO. 479 CHONGYANG ROAD
- **STREET 2:** NANGANG DISTRICT
- **CITY:** TAIPEI CITY
- **PROVINCE COUNTRY:** F5
- **ZIP:** 115010
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wang Ching-Dong
- **CENTRAL INDEX KEY:** 0002124675

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 1945 OLD GALLOWS ROAD
- **STREET 2:** SUITE 260
- **CITY:** VIENNA
- **STATE:** VA
- **ZIP:** 22182

## Exhibit 7.1

**Exhibit 7.1**

**JOINT FILING AGREEMENT**

The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-l(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

Date: June 18, 2026

---

| | | |
|:---|:---|:---|
| **Ching-Dong Wang** | **Ching-Dong Wang** | **Ching-Dong Wang** |
| By: | /s/ Ching-Dong Wang | /s/ Ching-Dong Wang |
|  | Name: | Ching-Dong Wang |
| **SL Science Holding Limited** | **SL Science Holding Limited** | **SL Science Holding Limited** |
| By: | /s/ Ching-Dong Wang | /s/ Ching-Dong Wang |
|  | Name: | Ching-Dong Wang |
|  | Title: | Director |
| **SL Link Co., Ltd.** | **SL Link Co., Ltd.** | **SL Link Co., Ltd.** |
| By: | /s/ Ching-Dong Wang | /s/ Ching-Dong Wang |
|  | Name: | Ching-Dong Wang |
|  | Title: | Chairman and Chief Executive Officer |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**SL Science Holding Ltd**

*(Name of Issuer)*

**Ordinary shares, par value $0.00001 per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Ching-Dong Wang**<br>11th Floor, No. 479 Chongyang Road,<br>Nangang District<br>Taipei F5 115010<br>886-2-26516826

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/12/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ching-Dong Wang** | Name of reporting person<br>**Ching-Dong Wang** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**F5** | Citizenship or place of organization<br>**F5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**333832129.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**333832129.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**333832129.00** | Aggregate amount beneficially owned by each reporting person<br>**333832129.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**59.53%** | Percent of class represented by amount in Row (11)<br>**59.53%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Represents 333,832,129 ordinary shares, par value $0.00001 per share (the "Ordinary Shares"), of SL Science Holding Limited, a company incorporated in the Cayman Islands (the "Issuer"), beneficially owned by Ching-Dong Wang, including (i) 329,286,823 Ordinary Shares held by SL Link Holding Ltd., and (ii) 4,545,306 Ordinary Shares held by SL Link Co., Ltd. The percentage listed in Row 13 is based on a total of approximately 560,759,757 Ordinary Shares issued and outstanding as a result of the completion of the Business Combination (as defined herein) on June 12, 2026, which does not include 260,000 Ordinary Shares convertible on December 12, 2026 from 780,000 preferred shares, par value $0.00001 per share (the "Preferred Shares"), issued and outstanding as of June 18, 2026. For more information regarding the Business Combination, see Item 4 of this Schedule 13D.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**SL Link Holding Ltd.** | Name of reporting person<br>**SL Link Holding Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**329286823.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**329286823.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**329286823.00** | Aggregate amount beneficially owned by each reporting person<br>**329286823.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**58.72%** | Percent of class represented by amount in Row (11)<br>**58.72%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** SL Link Holding Ltd. is a company incorporated in the Cayman Islands which is owned equally by Ching-Dong Wang and his spouse. Ching-Dong Wang is the sole director of SL Link Holding Ltd. As a result, Ching-Dong Wang is deemed to have voting and dispositive power over the securities of the Issuer held by SL Link Holding Ltd. The percentage listed in Row 13 is based on a total of approximately 560,759,757  Ordinary Shares issued and outstanding on a fully converted basis as a result of the completion of the Business Combination (as defined herein) on June 12, 2026, which does not include 260,000 Ordinary Shares convertible on December 12, 2026 from 780,000 Preferred Shares issued and outstanding as of June 18, 2026. For more information regarding the Business Combination, see Item 4 of this Schedule 13D.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**SL Link Co., Ltd.** | Name of reporting person<br>**SL Link Co., Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**F5** | Citizenship or place of organization<br>**F5** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4545306.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4545306.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4545306.00** | Aggregate amount beneficially owned by each reporting person<br>**4545306.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.81%** | Percent of class represented by amount in Row (11)<br>**0.81%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** SL Link Co., Ltd. is a company incorporated in Taiwan. Ching-Dong Wang owns a 50.63% equity interest in SL Link Co., Ltd., and is the Chairman of the Board and Chief Executive Officer of SL Link Co., Ltd. As a result, Ching-Dong Wang is deemed to have voting and dispositive power over the securities of the Issuer held by SL Link Co., Ltd. The percentage listed in Row 13 is based on a total of approximately 560,759,757 Ordinary Shares issued and outstanding on a fully converted basis as a result of the completion of the Business Combination (as defined herein) on June 12, 2026, which does not include 260,000 Ordinary Shares convertible on December 12, 2026 from 780,000 Preferred Shares issued and outstanding as of June 18, 2026. For more information regarding the Business Combination, see Item 4 of this Schedule 13D.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary shares, par value $0.00001 per share

**(b) Name of Issuer:**
SL Science Holding Ltd

**(c) Address of Issuer's Principal Executive Offices:**
11/F, NO. 479 CHONGYANG ROAD, Nangang District, TAIPEI CITY, F5, 115010

**Item 4. Purpose of Transaction**

On June 12, 2026, SL Bio and HSPT completed a business combination pursuant to the business combination agreement, dated May 9, 2025 (the "Business Combination Agreement"), by and among the Issuer, HSPT, CW Mega Limited, a Cayman Islands exempted company limited by shares and a wholly-owned subsidiary of the Issuer ("Merger Sub I"), WW Century Limited, a Cayman Islands exempted company limited by shares and a wholly-owned subsidiary of the Issuer ("Merger Sub II"), and SL Bio, under which, among other things, (i) Merger Sub I will merge with and into HSPT, with HSPT as the surviving entity and a wholly-owned subsidiary of the Issuer (the "First Merger"), and (ii) following the First Merger, Merger Sub II will merge with and into SL Bio, with SL Bio as the surviving entity and a wholly-owned subsidiary of the Issuer (the "Second Merger," and together with the First Merger and the other transactions contemplated by the Business Combination Agreement, the "Business Combination"). Upon the consummation of the Business Combination, each of HSPT and SL Bio became a subsidiary of the Issuer, and HSPT's shareholders and SL Bio's shareholders received Ordinary Shares of the Issuer. The Reporting Persons, as shareholders of SL Bio, received approximately an aggregate of 333,832,129 Ordinary Shares as a result of the completion of the Business Combination. Depending on prevailing market, economic and other conditions, the Reporting Persons may from time to time acquire additional Ordinary Shares or engage in discussions with the Issuer concerning future acquisitions of its shares. Such acquisitions may be made by means of open-market purchases, privately negotiated transactions, direct acquisitions from the Issuer or otherwise. Except as set forth in this Item 4, the Reporting Persons have no plans or proposals that relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present board of directors of the Issuer (the "Board") or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the Board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above. The Reporting Persons may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of this Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The responses to Items 7 - 13 of the cover pages of this Schedule 13D are incorporated herein by reference into this Item 5(a). The aggregate number and percentage of Ordinary Shares beneficially or directly owned by the Reporting Persons is based upon a total of approximately 560,759,757 Ordinary Shares issued and outstanding as a result of the completion of the Business Combination, which does not include 260,000 Ordinary Shares convertible on December 12, 2026 from 780,000 Preferred Shares issued and outstanding as of June 18, 2026. The Reporting Persons beneficially own 333,832,129 Ordinary Shares, representing approximately 59.53% of the issued and outstanding Ordinary Shares.

**(b)**
The responses to Items 7 - 13 of the cover pages of this Schedule 13D are incorporated herein by reference into this Item 5(b). The beneficial ownership of the Reporting Persons is 333,832,129 Ordinary Shares, representing approximately 59.53% of the issued and outstanding Ordinary Shares.

**(c)**
Other than the disposition of the Ordinary Shares as reported in this Schedule 13D, no transactions in the Ordinary Shares were effected during the past sixty (60) days by the Reporting Persons.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Item 4 of this Schedule 13D are hereby incorporated by reference into this Item 6.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ching-Dong Wang

**Signature:** /s/ Ching-Dong Wang

**Name/Title:** Ching-Dong Wang

**Date:** 06/18/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** SL Link Holding Ltd.

**Signature:** /s/ Ching-Dong Wang

**Name/Title:** Ching-Dong Wang/Director

**Date:** 06/18/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** SL Link Co., Ltd.

**Signature:** /s/ Ching-Dong Wang

**Name/Title:** Ching-Dong Wang/ Chairman and Chief Executive Officer

**Date:** 06/18/2026